COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article Access statistics

Viewed: 119

Emailed: 0

PDF Downloaded: 121

IP Indian Journal of Immunology and Respiratory Medicine

Therapeutic efficacy of Gefitinib in advanced NSCLC patients

Full Text PDF Share on Facebook Share on Twitter

Research Article

Author Details : S Mathanraj, Deepa Kameswari P*, D Biswajith, S Vinodkumar

Volume : 4, Issue : 4, Year : 2019

Article Page : 224-229

Suggest article by email


Introduction: Lung cancer uprises from the respiratory epithelium cells is divided into two broad
categories; Non–small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC), derived from cells
exhibiting Neuro-endocrine characteristics which is highly malignant tumour. The current drug therapy
of Gefitinib has little evidence for its efficacy and safety profile in Indian patients.
Aim: The research was focused to assess the efficacy of Gefitinib in advanced Non-small cell lung cancer.
Materials and Methods: It is a retrospective study, done during the study period January 2009 to June
2012, and the number of NSCLC patients was 25 cases.
Results: Of the 25 cases, 13 (52%) were males and 12 (48%) were females. The factors affecting survival
have been studied there was a significant difference in survival between male and female sex (males 7.2
months; females 10.9 months). NSCLC patients were also having pleural effusion in 15 (60%) patients;
fluid was hemorrhagic in 13 cases and straw coloured in 2 cases. The mean ADA level was 18.3 IU (5-43)
and the Cell count was predominantly lymphocytic. The pleural fluid cytology was positive for malignant
cells in 9 cases (60%) and the pericardial effusion was present in 4 patients. Calculating the objective
response rate, there was no patients with complete response, 3 (16, 7%) with partial response, 9 (50%)
cases with Stable disease and 6 (33.2%) had progressive disease and the overall rate of survival was 10.9
months (range 8.2-13.6). The most common adverse effect observed was diarrhea reported in 5 cases
(20%), followed by rash in 4 (16.7%) and mucositis in 4 (16.7%) of cases.
Conclusion: From the current study, it’s likely that, its use may not rapidly move NSCLC from advanced
late-stage disease to earlier and less-advanced stages, but it is observed as a well tolerated drug that shows
significant survival advantage with minimal toxicity.

Keywords: Gefitinib, Non–small cell lung cancer (NSCLC), EGFR.

Doi : 10.18231/j.ijirm.2019.052

How to cite : Mathanraj S, Deepa Kameswari P, Biswajith D , Vinodkumar S, Therapeutic efficacy of Gefitinib in advanced NSCLC patients. IP Indian J Immunol Respir Med 2019;4(4):224-229

Copyright © 2019 by author(s) and IP Indian J Immunol Respir Med. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (